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Hyperglycemia results in oxidative stress and leads to neuronal apoptosis in the brain.
Diabetes studies show that microglia participate in the progression of neuropathogenesis
through their involvement in inflammation in vivo and in vitro. In high-glucose-induced
inflammation, apoptosis signal regulating kinase 1 (ASK1) triggers the release of
apoptosis cytokines and apoptotic gene expression. MicroRNA-Let7A (miR-Let7A) is
reported to be a regulator of inflammation. In the present study, we investigated
whether miR-Let7A regulates the function of microglia by controlling ASK1 in response
to high-glucose-induced oxidative stress. We performed reverse transcription (RT)
polymerase chain reaction, Taqman assay, real-time polymerase chain reaction, and
immunocytochemistry to confirm the alteration of microglia function. Our results show
that miR-Let7A is associated with the activation of ASK1 and the expression of
anti-inflammatory cytokine (interleukin (IL)-10) and Mycs (c-Myc and N-Myc). Thus,
the relationship between Let-7A and ASK1 could be a novel target for enhancing the
beneficial function of microglia in central nervous system (CNS) disorders.
Keywords: Microglia BV2, microRNA-Let7A (miR-Let7A), apoptosis signal regulating kinase 1 (ASK1), cytokine,
N-Myc, c-Myc
Introduction
Microglia are major glial cells with an important role in defending the brain against invading
microorganisms, as they are the resident immunocompetent and phagocytic cells in the central
nervous system (CNS) (Kreutzberg, 1996). However, the improper activation of microglia is
related to neuronal damage in CNS diseases via the overproduction of free radicals and
the secretion of various cytokines (Dringen, 2005; Krady et al., 2005; Frank-Cannon et al.,
2009). Microglia activation is linked to changes in both their morphology, including cell
hypertrophy (Tsuda et al., 2008), and their function (Wodarski et al., 2009; Xu et al., 2009).
Recently, microglia have been found to exhibit two broad phenotypes: M1 and M2 types
(Colton, 2009) Activated M1-type microglia release various neuroinflammatory mediators such
as reactive oxygen species (ROS) (Quan et al., 2007) and pro-inflammatory cytokines (Min
et al., 2003; Zhang et al., 2013), including interleukin (IL)-1β, IL-6, and tumor necrosis factor
(TNF)-α, in the CNS (Hanisch, 2002). By contrast, activated M2-type microglia appear to
suppress inflammation by producing anti-inflammatory cytokines, including IL-10 (Yang et al.,
2009), tumor growth factor (TGF)-β (Mantovani et al., 2004; Martinez et al., 2008), and IL-
4 (Stein et al., 1992). Hyperglycemia impairs neuronal function and leads to oxidative stress
(Catanzaro et al., 2013). Cerebral cortex neurons become damaged by high-glucose-induced
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oxidative stress according to an experimental diabetes study
(Arnal et al., 2010). The state of high-glucose induced by
hyperglycemia leads to severe neuronal apoptosis in the brain
(Knudsen et al., 1989; Sredy et al., 1991; Li and Sima, 2004;
Sima et al., 2004) and impaired cognition (Li et al., 2002, 2003).
Several studies report that activated microglia are associated with
neurodegeneration (Klein et al., 2004) and structural changes,
including hippocampal injury and cerebral atrophy, in animal
models of diabetes (Musen et al., 2006; Kodl et al., 2008) as
well as the progression of brain atrophy and cognitive decline in
elderly diabetes patients (van Elderen et al., 2010). Furthermore,
a recent in vitro study demonstrates that hyperglycemia increases
microglial vulnerability to lipopolysaccharide (LPS)-induced
inflammation (J. Y. Wang et al., 2001) and induces the secretion
of pro-inflammatory cytokines and ROS and the activation
of apoptotic signaling pathways, such as the nuclear factor
kappa B (NF-κB) signaling pathway (Quan et al., 2007). Some
research demonstrates that the inhibition of microglia activation
attenuates diabetes-induced inflammatory cytokine production
and reduces apoptosis (Krady et al., 2005). How microglia
activation is modulated in high-glucose stress is a crucial
problem to solve for hyperglycemia-induced neuroinflammatory
diseases. Hyperglycemia-induced oxidative stress accelerates cell
senescence and activates apoptosis signal regulating kinase 1
(ASK1) (Yokoi et al., 2006), which is a member of the mitogen-
activated protein (MAP) kinase kinase kinase group associated
with apoptosis signaling (Ichijo et al., 1997; Tobiume et al.,
2001). ASK1 can cause apoptosis through non-transcription-
or transcription-dependent mechanisms (Tobiume et al., 2001).
MicroRNAs (miRNAs), which are endogenous 22-nucleotide
RNAs that bind to the 3′-untranslated region of amessenger RNA
(mRNA) target, regulate oxidative and inflammatory state (Marin
et al., 2013) by affecting gene expression (Martinez and Tuschl,
2004; Du and Zamore, 2005; Schamberger et al., 2012). Several
microRNAs including miR-155 (Arango et al., 2015; Cheng et al.,
2015; Tan et al., 2015), miR-146 (Schulte et al., 2013; Echavarria
et al., 2015), and miR-21(Quinn and O’Neill, 2011) reported the
relationship with inflammation in various condition. miR-21,
miR-126, and miR-210 are downregulated under in vitro diabetic
conditions and in Type 1 diabetic patients (Osipova et al., 2014).
In addition, miR-146a (Baldeon et al., 2014; Wang et al., 2014),
miR-155(Lin et al., 2014), miR-133 (Xiao et al., 2007), miR-1,
and miR-206 (Shan et al., 2010) regulate diverse mechanisms in
high-glucose stress. Among miRNAs, miR-Let7 in particular is
known to regulate glucose metabolism (Zhu et al., 2011) and is
linked to inflammatory pathways (Iliopoulos et al., 2009). Here,
we investigated the relationship between miR-Let7A and ASK1
activation in microglia function against high-glucose stress. Our
results increase our understanding of themechanisms underlying
microglia function in hyperglycemia-induced oxidative stress
states.
Materials and Methods
Microglia Culture and D-Glucose Treatment
Murine BV2 microglial cells were obtained from Prof. Eun-hye
Joe (Ajou University School of Medicine, Chronic Inflammatory
Disease Research Center) and cultured in Dulbecco’s Modified
Eagle’s Medium (Gibco, NY, USA) supplemented with 10%
fetal bovine serum (Gibco, NY, USA) and 100µg/ml penicillin-
streptomycin (Gibco, NY, USA) at 37◦C in a humidified
atmosphere containing 5% CO2. Also we treated D-glucose
25mM, 60mM and 90mM, and 120mM (Sigma, St. Louis, MO,
USA) in microglia cells, considering other in vitro studies in high
glucose concentrations (25mM -120mM) (Quan et al., 2007,
2011; Dey et al., 2015; Zhang et al., 2015).
miRNA Transfection
BV2 microglia were treated with miR-Let7A mimic or anti-
miR-Let7A. Let-7A mimic (Let-7A precursor molecules are
considered to be processed into mature miRNA by mimicking
the Let-7A natural shearing process) and anti-Let-7A (Let7A
inhibitor) were purchased from Ambion (Austin, TX, USA). For
the transfection of RNA duplexes, a 20 nM final concentration
of Let-7A miRNA mimic or Let-7A inhibitor was mixed with
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in Opti-
MEM medium and incubated at room temperature for 10min.
Themixture was added to cells in 6-well plates. After cells reached
60% confluence, they were harvested for total protein or RNA
extraction. ASK1 inhibitor (NQDI-1) was purchased from Tocris
Bioscience (Bristol, UK). BV2 microglial cells were pretreated
with ASK1 inhibitor (600 nM) to inhibit ASK1 activation 2 h
before high-glucose injury.
Cell Viability Assay
BV2 microglia (2 × 105 cells/ml) were seeded in 96-well plates
to examine the effects of all experimental treatments. Cells were
then rinsed with phosphate-buffered saline (PBS), and culture
medium was replaced with serum-free medium. Next, 100µl
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (Sigma, St. Louis, MO, USA) solution (5mg/ml in PBS)
was added per well. After 1 h of incubation, the medium was
removed, and dimethyl sulfoxide was added to solubilize the
purple formazan product of the MTT reaction. The supernatant
from each well was measured using an ELISA plate reader at a
wavelength of 570 nm with background subtraction at 650 nm.
All experiments were repeated at least six times. Cell viability
was not considered 100% for any treatment group. Cell viability
was expressed as a percentage relative to the control group
value.
Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
To examine the expression of IL-10, c-Myc, and N-Myc in
BV2 microglia, RT-PCR was performed using each primer.
Briefly, samples were lysed with Trizol reagent (Invitrogen,
Carlsbad, CA, USA), and total RNA was extracted according
to the manufacturer’s protocol. cDNA synthesis from mRNA
and sample normalization were performed. PCR was performed
using the following thermal cycling conditions: 95◦C for 10min;
35 cycles of denaturing at 95◦C for 15 s, annealing at 70◦C
for 30 s, elongation at 72◦C for 30 s; final extension at 72◦C
for 10min; and holding at 4◦C. PCR was performed using
the following primers (5′–3′); IL-10 (F): CCAAGCCTTATC
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GGAAATGA, (R) TTTTCACAGGGGAGAAATCG; c-Myc
(F): TCAAGAGGCGAACACACAAC, (R): GGCCTTTTCATT
GTTTTCCA; N-Myc (F): GTCACCACATTCACCATCACTGT,
(R): AGCGTGTTCAATTTTCTTTAGCA; GAPDH (F): GGCA
TGGACTGTGGTCATGAG, (R): TGCACCACCAACTGCT
TAGC. PCR products were electrophoresed in 1.5% agarose gels
and stained with ethidium bromide.
Quantitative Real-time PCR
To examine the amount of TNF-α, IL-6, IL-10, and ASK1
mRNA in BV2 cells under high-glucose conditions, quantitative
real-time PCR was performed using each primer. Total cellular
RNA was extracted from BV2 microglia using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. RNA was mixed with One Step SYBR R© Prime
Script TM RT-PCR Kit II (Takara, Otsu, Shiga, Japan) and
specific primers in a total reaction volume of 20µl. PCR was
performed using the following primers (5′–3′); TNF-α (F):
CAAGGGACAAGGCTGCCCCG, (R): GCAGGGGCTCTT
GACGGCAG; IL-6 (F): AACGATGATGCACTTGCAGA, (R):
CTCTGAAGGACTCTGGCTTTG; IL-10 (F): CCAAGCCT
TATCGGAAATGA, (R): TTTTCACAGGGGAGAAATCG;
ASK1 (F): AGGACGGAGACTGTGAGGGT, (R): GTCCTGCA
TAGACGATCCCAT; GAPDH (F): GGCATGGACTGTGGTC
ATGAG, (R): TGCACCACCACTGCTTAGC. Amplification
cycles were carried out at 42◦C for 5min, 95◦C for 10 s, 95◦C for
5 s, 60◦C for 34 s, and 65◦C for 15 s. Quantitative SYBR Green
real-time PCR was performed with an ABI prism 7500 Real-Time
PCR System (Life Technologies Corporation, CA, USA) and
analyzed with comparative Ct quantification (Popivanova et al.,
2008). GAPDH was amplified as an internal control. The Ct
value for GAPDH was subtracted from the Ct values for each
gene (1Ct). The 1Ct values of treated cells were compared with
those of untreated cells.
Taqman Assay
Total RNA was extracted from cells using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. For quantitative analysis of miR-Let7A, reverse
transcription (RT) was performed using Taqman Micro RNA RT
kit (Takara, Otsu, Shiga, Japan) according to the manufacturer’s
instructions with 10 ng total RNA. PCR reactions were
then performed according to manufacturer’s instructions to
quantify the expression level of miR-Let7A using Taqman
Universal PCR Master Mix, No Amp Erase UNG (Applied
Biosystems, Foster City, CA, USA), and Taqman microRNA
assay (Takara, Otsu, Shiga, Japan) for the miR-Let7A of
interest. The PCR amplification was performed in ABI 7500
Real Time PCR (Life Technologies Corporation, CA, USA)
at 95◦C for 10min, followed by 40 cycles of 95◦C for 15 s
and 60◦C for 60 s. The PCR incubation profile was extended
to 40 cycles for miR-Let7A. The PCR primers for Let-7A
were (F): 5′-GCGCCTGAGGTAGTAGGTTG-3′ and (R): 5′-
CAGTGCAGGGTCCGAGGT-3′. The PCR primers for U6
were (F): 5′-CTCGCTTCGGCAGCACATATACT-3′ and (R): 5′-
ACGCTTCACGAATTTGCGTGTC-3′, respectively. The data
were uniformly normalized to the internal control U6, and
relative expression levels were evaluated using the 2−11Ct
method. All experiments were run in triplicate (Zhang et al.,
2014).
Western Blot Analysis
After drug treatment and exposure to high glucose stress, BV2
cells were washed twice with ice-cold PBS, scraped, and collected.
BV2 cell pellets were lysed with ice-cold RIPA buffer (Sigma-
Aldrich, St. Louis, MO, USA). The lysates were centrifuged
at 13,200 rpm for 1 h at 4◦C to produce whole-cell extracts.
Protein content was quantified using the BCA protein assay
kit (Pierce, IL, USA). Protein (30µg) was separated on a 10%
SDS-polyacrylamide gel and transferred onto a polyvinylidene
difluoride membrane. After blocking with 5% bovine serum
albumin in TBS/Tween (20 nM Tris (pH 7.2), 150mM NaCl,
0.1% Tween 20) for 1 h at room temperature, immunoblots
were incubated overnight at 4◦C with primary antibodies that
specifically detect phosphorylation-ASK1 (p-ASK1) (1:1000; Cell
signaling biotechnology, Danvers, MA, USA), ASK1 (1:1000;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), or β-actin
(1:2000; Cell Signaling, Danvers, MA, USA). Blots were then
incubated with horseradish peroxidase-linked anti-mouse or -
rabbit IgG antibodies (Abcam, Cambridge, MA, USA) for 1 h
at room temperature. Protein bands were detected and analyzed
using enhanced chemiluminescence (ECL; Pierce, IL, USA)(Song
et al., 2014).
Immunocytochemistry
BV2 microglia were washed three times with PBS for
immunostaining and blocked for 30min. BV2 microglia
were then incubated with primary antibodies overnight at 4◦C.
The following primary antibodies were used: anti-goat CD68
(1:200, Millipore, Billerica, MA, USA) and anti-rabbit CD206
(1:200, Millipore, Billerica, MA, USA). After incubating BV2
microglia with the primary antibodies, cells were washed with
PBS three times for 3min each. Next, samples were incubated
with fluorescein isothiocyanate (FITC)-conjugated donkey
anti-goat (1:200, Jackson Immunoresearch, West Grove, PA,
USA) or rhodamine-conjugated goat anti-rabbit (1:200, Jackson
Immunoresearch, West Grove, PA, USA) for 2 h at room
temperature. BV2 microglia were washed with PBS three times
for 3min each and then counterstained with 1µg/ml 4′, 6-
diamidino-2-phenylindole (DAPI) (1:100, Invitrogen, Carlsbad,
CA, USA) for 10min at room temperature. Fixed samples were
imaged using a Zeiss LSM 700 confocal microscope (Carl Zeiss,
Thornwood, NY, USA).
Statistical Analysis
Statistical analyses were carried out using SPSS 18.0 software
(IBM Corp., Armonk, NY, USA). All data are expressed as
mean ± standard error of the mean (S.E.M.). Significant group
differences were determined by one-way analysis of variance
followed by Bonferroni post-hoc multiple comparisons tests.
Each experiment consisted of three replicates per condition.
Differences were considered statistically significant at ∗p < 0.05
and ∗∗p < 0.001.
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Results
Inhibition of ASK1 Activation Enhances Cell
Viability against High-glucose Stress
To investigate the viability of BV2 microglia in high-glucose
conditions, we conducted an MTT assay with different
concentration of glucose (Figure 1A). Cell viability was reduced
by glucose treatment (25, 60, 90, or 120mM). After pre-
treatment with ASK1 inhibitor (600 nM, TOCRIS, Bristol, UK),
the viability of high-glucose-exposed microglia significantly
increased by 20% compared with that of the high-glucose
treatment alone group (Figure 1A). Because cell viability
showed the largest change by ASK1 inactivation in the
120mM glucose condition, we used this concentration in
subsequent experiments. To determine the whether ASK1
directly participates in the alteration of cell viability against
high-glucose stress, we conducted quantitative real time-PCR
using ASK1-specific primer (Figures 1B,C). ASK1 expression
was increased in the 25mM glucose condition and was markedly
reduced after ASK1 inhibitor pre-treatment (Figure 1B). ASK1
expression was increased in the 120mM glucose condition and
was significantly reduced after ASK1 inhibitor pre-treatment
(Figure 1C).
Measurement of M1- and M2-type Microglia after
High-glucose Injury
To observe the function of microglia, we investigated the
expression of CD68 (Figure 2A) and CD206 (Figure 2B)
in 25mM and 120mM high glucose concentration using
immunocytochemical analysis. The expression of CD68
was considerably increased in the high-glucose treatment
group (120mM) and was attenuated by the inhibition of
ASK1 activation (Figure 2A). The expression of CD206 was
considerably reduced in the high-glucose treatment group
(120mM) and was slightly increased by the inhibition of ASK1
(Figure 2B).
Measurement of Cytokine Levels in Microglia
after High-glucose Injury
To examine the mRNA level of cytokines in microglia following
the inhibition of ASK1 activation in high-glucose injury
(25mM and 120mM), we conducted quantitative real-time PCR
FIGURE 1 | The measurement of cell viability and the expression of
ASK1 in microglia under high glucose condition. (A)MTT assay. The
graph showed that BV2 microglia in the high glucose treatment groups (25,
60, 90, 120mM) exhibited decrease of cell viability compared to the normal
control group. BV2 microglia in all ASK1 inhibitor pre-treatment groups
exhibited increase of cell viability after high glucose injury compared to the
normal control group. Especially, the microglia in the glucose 120mM with
ASK1 inhibitor conditions showed markedly the increase of cell viability
comparison with ASK1 inhibitor treatment group. Each experiment included
the six repeats per condition. (B) The measurement of relative quantitative
mRNA level. The graph showed the mRNA level of ASK1 in glucose condition.
In high glucose 25mM treatment group, the level of ASK1 mRNA increased
evidently compared to the no treatment group. ASK1 inhibitor pre-treatment
attenuated the expression of ASK1 in microglia in spite of 25mM high glucose
condition. GAPDH was used as a control. Each experiment included the three
repeats per condition. Each experiment included the three repeats per
condition. Data were expressed as mean ± S.E.M, and were analyzed
statistically using One-Way ANOVA, followed by Bonferroni’s post hoc.
**p < 0.001. (C) The measurement of relative quantitative mRNA level. The
graph showed the mRNA level of ASK1 in glucose condition. In high glucose
120mM treatment group, the level of ASK1 mRNA increased evidently
compared to the no treatment group. ASK1 inhibitor pre-treatment attenuated
the expression of ASK1 in microglia in spite of 120mM high glucose condition.
GAPDH was used as a control. Each experiment included the three repeats
per condition. Each experiment included the three repeats per condition. Data
were expressed as mean ± S.E.M, and were analyzed statistically using
One-Way ANOVA, followed by Bonferroni’s post hoc. *p < 0.05, **p < 0.001.
RQ, relative quantitative value of mRNA via GAPDH.
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FIGURE 2 | The immunocytochemical images to determine the
microglia phenotype. (A) The expression of CD 68 (considered as themarker
of M1 type microglia) was evaluated by immunocytochemistry. This image
showed that high glucose 120mM treated microglia expressed more the CD
68 protein in microglia than the untreated microglia. Also, the ASK1 inhibitor
pre-treated microglia showed the attenuation of CD 68 expression compared
with the normal microglia. (B) The expression of CD 206 (considered as the
marker of M2 type microglia) was examined by immunocytochemistry. This
image showed that high glucose 120mM treated microglia expressed lesser
the CD 206 protein in microglia than the untreated microglia. In addition, the
ASK1 inhibitor pre-treated microglia showed the increase of CD 206
expression compared with the normal microglia. Scale bar: 200µm, 4′,
6-diamidino-2-phenylindole (DAPI): blue, CD 68: green, CD 206: red. Glu
(25mM): glucose 25mM treatment, Glu (120mM): glucose 120mM treatment.
(Figures 3A–D) and RT-PCR (Figure 3E). The mRNA level of
pro-inflammatory cytokine TNF-α in microglia was increased
in the high-glucose treatment group (Figures 3A,C) and was
dramatically reduced by ASK1 inhibition (Figures 3A,C). The
mRNA level of pro-inflammatory cytokine IL-6 in microglia
was significantly increased in the high-glucose treatment
group (Figures 3B,D) and was decreased by ASK1 inhibition
(Figure 3B). The mRNA level of anti-inflammatory cytokine IL-
10 in microglia was significantly decreased in the high-glucose
treatment group (Figure 3E) and tended to increase after ASK1
inhibition (Figure 3E). Taken together, these results indicate that
the inhibition of ASK1 activation regulates the expression of
cytokines.
Measurement of miR-Let7A Level in BV2
Microglia after High-glucose Injury
To examine levels of miR-Let7A in microglia following the
inhibition of ASK1 activation in high-glucose injury (25mM
and 120mM), we conducted a Taqman assay (Figure 4). The
level of miR-Let7A in microglia was significantly increased
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FIGURE 3 | The mRNA level of cytokines on microglia in high
glucose stress. The mRNA levels of TNF-alpha, IL-6, IL-10 were
measured using quantitative real time–PCR (A–D) and reverse
transcription-PCR (E). (A) The mRNA level of TNF-alpha was increased in
the high glucose treatment group (25mM) and reduced in ASK1 inhibitor
pre-treated high glucose group. (B) The mRNA amount of IL-6 was
increased in the high glucose treatment group (25mM) and significantly
decreased in ASK1 inhibitor pre-treated high glucose group. (C) The
mRNA level of TNF-alpha was increased in the high glucose treatment
group (120mM) and reduced in ASK1 inhibitor pre-treated high glucose
group. (D) The mRNA amount of IL-6 was increased in the high glucose
treatment group (120mM) and significantly decreased in ASK1 inhibitor
pre-treated high glucose group (120mM). (E) The mRNA level of IL-10
exhibited decrease of expression in the high glucose treatment group
(120mM) whereas it significantly increased in ASK1 inhibitor pre-treated
high glucose group (120mM). GAPDH was used as a control. Each
experiment included the 3 repeats per condition. Data were expressed as
mean ± S.E.M, and were analyzed statistically using One-Way ANOVA,
followed by Bonferroni’s post hoc. *p < 0.05, **p < 0.001. RQ, relative
quantitative value of mRNA via GAPDH.
in the high-glucose treatment group [25mM (Figure 4A) and
120mM (Figure 4B)] and was reduced by ASK1 inhibition
(Figure 4). The level of miR-Let7A in microglia in the high-
glucose treatment group was almost the same as that in microglia
with overexpression of Let7A plus ASK1 inactivation in the
high-glucose condition (Figure 4).
Relationship between ASK1 and miR-Let7A in
High-glucose Injury
To confirm a relationship between miR-Let7A and ASK1
activation in microglia in high-glucose injury, we conducted
quantitative real-time PCR (Figure 5A) and RT PCR
(Figures 5B,C) and western blot analysis (Figures 5D–F).
The mRNA level of ASK1 in microglia was significantly
increased in the high-glucose treatment group and was reduced
in the miR-Let7A mimic transfection group (Figure 5A).
Also, the mRNA level of ASK1 was reduced by Let7A mimic
transfection under glucose 120mM treatment condition
(Figure 5A). The mRNA level of ASK1 in BV2 cells was reduced
by Let7A mimic treatment (Figure 5B), and ASK1 inhibitor
treatment (Figure 5C) in comparison with the only glucose
120mM treatment group (Figures 5B,C). The activation of
ASK1 [the phosphorylation of ASK1(p-ASK1)/ASK1 protein
level] was increased in glucose 120mM treatment group, while
the increased phosphorylation of ASK1 in glucose 120mM
treatment was attenuated by the inhibition of ASK1 (Figure 5E).
The activation of ASK1 was reduced in Let7A treatment group
(Figure 5F).
Effect of ASK1 Inhibition and miR-Let7A
Overexpression on Cytokine Expression in
High-glucose Injury
To examine changes in cytokine mRNA levels in microglia after
ASK1 inactivation and miR-Let7A overexpression under high-
glucose injury, we conducted quantitative real-time PCR. The
mRNA level of pro-inflammatory cytokine IL-6 in microglia
was significantly increased in the high-glucose treatment group
(Figure 6A) and was also increased in the Let7A mimic
transfection group. In addition, the expression of IL-6 was
decreased in the ASK1 inactivation group and in the ASK1
inhibition plus Let7A overexpression group after high-glucose
injury (Figure 6A). The mRNA level of anti-inflammatory
cytokine IL-10 in microglia was reduced in the high-glucose
treatment group (Figure 6B) and was increased in themiR-Let7A
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FIGURE 4 | The measurement of miR-Let7A on microglia in high
glucose stress. (A) In high glucose 25mM treatment group, miR-Le7A level
was considerably increased in comparison with the no treatment group.
Under high glucose stress, ASK1 inhibitor inhibited the reduced level of
miR-Let7A compared with the high glucose treatment group. The
co-treatment with glucose 25mM and miR-Let7A mimic showed higher level
of miR-Le7A than high glucose treatment group. U6 was used as a control.
Each experiment included the three repeats per condition. Data were
expressed as mean ± S.E.M, and were analyzed statistically using One-Way
ANOVA, followed by Bonferroni’s post hoc. **p < 0.001. (B) In high glucose
120mM treatment group, miR-Le7A level was considerably increased
compared to the no treatment group. Under high glucose stress, ASK1
inhibitor inhibited the reduced level of miR-Let7A compared with the high
glucose treatment group. The co-treatment with ASK1 inhibitor and
miR-Let7A mimic showed lesser level of miR-Le7A than high glucose
treatment group. U6 was used as a control. Each experiment included the 3
repeats per condition. Data were expressed as mean ± S.E.M, and were
analyzed statistically using One-Way ANOVA, followed by Bonferroni’s post
hoc. **p < 0.001. RQ, relative quantitative value of mRNA via U6; ASK1
inhibitor, ASK1 inhibitor (600 nM) pre-treatment and high glucose injury
group/The inhibition of ASK1 activation group; Let7A mimic, Let7A over
expression group in high glucose condition; anti-Let7A, Let7A inhibition in
high glucose condition; Glucose (25mM), glucose 25mM treatment; Glucose
(120mM), glucose 120mM treatment.
overexpression group. In addition, the expression of IL-10 was
increased in the ASK1 inactivation group in the high-glucose
condition compared with that in the high-glucose treatment
alone group. In the inhibition of ASK1 plus Let7A overexpression
in high-glucose injury group, the expression of IL-10 was slightly
increased compared with that in the Let7A mimic transfection
group (Figure 6B).
Alteration of N-Myc and c-Myc Expression by
ASK1 Inhibition and Let7A Overexpression in
High-glucose Injury
To examine the regulation of N-Myc and c-Myc by ASK1
inhibition and miR-Le7A overexpression, we analyzed the
mRNA level of these factors using RT-PCR (Figure 7). The
mRNA level of N-Myc was increased in the high-glucose
condition (Figure 7A). The inhibition of ASK1 activation
markedly decreased N-Myc expression, whereas miR-Let7A
overexpression did not result in large changes in N-Myc mRNA
levels in the high-glucose condition (Figure 7A). Moreover, the
inhibition of ASK1 in the Let7A mimic transfection condition
decreased N-Myc mRNA level to almost the same value as
that for ASK1 inhibition under the high-glucose condition
(Figure 7A). Based on our findings, we assume that miR-
Let7A links ASK1 to N-Myc in the high-glucose condition.
In addition, the mRNA level of c-Myc was significantly
increased in the high-glucose condition (Figure 7B). The
inhibition of ASK1 activation decreased c-Myc expression, and
miR-Let7A overexpression led to a slight decrease of c-Myc
mRNA level under the high-glucose condition compared with
that for the high-glucose treatment alone group (Figure 7B).
Moreover, the inhibition of ASK1 plus Let7A overexpression
increased c-Myc mRNA level in the high-glucose condition
(Figure 7B).
Discussion
In the CNS, elevated glucose levels lead to severe neuronal
death and impaired cognition (Duarte et al., 2008; McCrimmon
et al., 2012). In hyperglycemic conditions, ASK1 is activated,
involving apoptotic gene expression (F. Wang et al., 2015).
miRNAs are small, 19− to 23−nucleotide RNA molecules that
play a role in regulating protein expression in cells (Cai et al.,
2010; Feng et al., 2010; Lu et al., 2010). miRNAs have been
implicated in various cellular processes such as proliferation and
apoptosis (Bartel, 2004; Bentwich et al., 2005). In particular,
previous studies suggest that miR-Let7A is associated with
apoptotic signaling in high-glucose conditions (Urbich et al.,
2008; Iliopoulos et al., 2009; Zhu et al., 2011; Perez et al., 2013).
Our results confirm the involvement of ASK1 in microglia cell
viability and activation in high-glucose conditions, consistent
with findings that ASK1 is associated with high-glucose-induced
endoplasmic reticulum stress and apoptosis (Jiang et al., 2015;
Wang et al., 2015). In addition, our results regarding the M1-
type marker CD 68 (Lemstra et al., 2007; Wojtera et al., 2012)
and M2-type marker CD 206 (Stein et al., 1992; Mulder et al.,
2014) indicate that the inhibition of ASK1 may induce activation
of M2-type microglia and affect signaling that suppresses the
inflammation response, suggesting that M2-type macrophages
protect cells from inflammation (Varin and Gordon, 2009;
Colton and Wilcock, 2010; Cherry et al., 2014). In the present
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FIGURE 5 | The measurement of ASK1 on microglia in high glucose
stress. (A) The mRNA level of ASK1 was evidently increased by glucose
treatment. Under high glucose stress, ASK1 inhibitor and the miR-Let7A
overexpression group inhibited the decreased level of miR-Let7A compared
to the normal control group. GAPDH was used as a control. Each experiment
included the three repeats per condition. Data were expressed as mean ±
S.E.M, and were analyzed statistically using One-Way ANOVA, followed by
Bonferroni’s post hoc. *p < 0.05, **p < 0.001, (B) The overexpression of
Let7A was significantly decreased the mRNA of ASK1 in glucose 120mM
treatment condition in comparison with the only glucose treatment group.
GAPDH was used as a control. Each experiment included the three repeats
per condition. Data were expressed as mean ± S.E.M, and were analyzed
statistically using One-Way ANOVA, followed by Bonferroni’s post hoc.
*p < 0.05. (C) The inhibition of ASK1 was significantly attenuated the mRNA
of ASK1 in glucose 120mM treatment condition in comparison with the only
glucose treatment group. GAPDH was used as a control. Each experiment
included the three repeats per condition. Data were expressed as mean ±
S.E.M, and were analyzed statistically using One-Way ANOVA, followed by
Bonferroni’s post hoc. *p < 0.05. (D) The phosphorylation of ASK1/ASK1
level was increased by glucose 120mM treatment compared to the normal
control group. Also the activation of ASK1 was reduced in the glucose with
Let7A overexpression in comparison with the only glucose treatment group.
ß-actin was used as a control. Each experiment included the three repeats
per condition. Data were expressed as mean ± S.E.M, and were analyzed
statistically using One-Way ANOVA, followed by Bonferroni’s post hoc.
*p < 0.05,**p < 0.001. (E) The activation of ASK1 was reduced by ASK1
inhibitor treatment under glucose 120mM treatment in comparison with the
ASK1 inhibitor treatment group. β-actin was used as a control. Each
experiment included the three repeats per condition. Data were expressed as
mean ± S.E.M, and were analyzed statistically using One-Way ANOVA,
followed by Bonferroni’s post hoc. *p < 0.05, **p < 0.001. (F) The activation
of ASK1 was reduced by Let7A mimic treatment compared with the no
treatment group. β-actin was used as a control. Each experiment included
the three repeats per condition. Data were expressed as mean ± S.E.M, and
were analyzed statistically using One-Way ANOVA, followed by Bonferroni’s
post hoc. *p < 0.05. ASK1 inhibitor, ASK1 inhibitor (600 nM) pre-treatment
and high glucose injury group/The inhibition of ASK1 activation group; Let7A
mimic, Let7A over expression group in high glucose condition; anti-Let7A,
Let7A inhibition in high glucose condition; p-ASK1: the phosphorylation of
ASK1.
study, a high-glucose state led to increases in the levels of pro-
inflammatory cytokines such as TNF-α and IL-6 (Varnum and
Ikezu, 2012) and decreases in the levels of anti-inflammatory
cytokine such as IL-10 (Ledeboer et al., 2000). Furthermore,
we found that inhibition of ASK1 attenuated the release
of pro-inflammatory cytokines and promoted the release of
anti-inflammatory cytokine such as IL-10 in high-glucose stress.
Moreover, more miR-Let7A expression occurred in the ASK1
activation condition than in the normal condition. Based on
our results, we assume that miR-Let7A may be linked to the
activation of ASK1 and may be involved in the expression of
cytokines in hyperglycemia. In the present study, the transfection
of miR-Let7A and anti-miR-Let7A led to ASK1 activation and
altered the expression of cytokines. In particular, miR-Let7A
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FIGURE 6 | The mRNA level of cytokines on microglia in high glucose
stress. The mRNA levels of IL-6, IL-10 in ASK1 inhibition and miR-Let7A
overexpression were measured using quantitative real time–PCR. (A) The
mRNA level of IL-6 was increased in the high glucose treatment group and
reduced in ASK1 inhibitor pre-treatment group. In high glucose condition, IL-6
mRNA level was attenuated as the inhibition of ASK1 activation. (B) The
mRNA level of IL-10 was reduced in the high glucose treatment group and
increased in ASK1 inhibitor pre-treatment group. In high glucose condition,
IL-10 mRNA level was attenuated through the overexpression of miR-Let7A
whereas the inhibition of ASK1 activation was promoted the expression of
IL-10. GAPDH was used as a control. Each experiment included the three
repeats per condition. Data were expressed as mean ± S.E.M, and were
analyzed statistically using One-Way ANOVA, followed by Bonferroni’s post
hoc. *p < 0.05, **p < 0.001. RQ, relative quantitative value of mRNA.
tended to reduce pro-inflammatory cytokines more than anti-
inflammatory cytokines. miR-Let7A regulated the expression of
cytokines more in the ASK1 inhibitor co-treatment group than
the miR-Let7A mimic transfection only group. Several studies
demonstrate that anti-inflammatory cytokines are regulated
through inhibition of ASK1 activation (Liu et al., 2012), and
ASK1 is involved in the production of inflammatory cytokines
in macrophages (Matsuzawa et al., 2005; Osaka et al., 2007;
Yuk et al., 2009). Considering previous evidence, our results
indicate that Let7A miRNA may strongly regulate the expression
of inflammatory cytokines by controlling ASK1 activation.
Specifically, our results show that miR-Let7A may affect the
expression of anti-inflammatory cytokines including IL-10 by
FIGURE 7 | The mRNA level of N-Myc and c-Myc on microglia in high
glucose stress. The mRNA levels of N-Myc and c-Myc were measured using
reverse transcription—PCR (A,B). (A) The mRNA level of N-Myc evidently
exhibited increase of expression in the high glucose treatment group whereas
it was decreased in ASK1 inhibitor pre-treated group. In ASK1 inhibition with
Let7A overexpression group, microglia expressed lower N-Myc mRNA level in
high glucose condition than only high glucose treatment group. (B) The mRNA
level of c-Myc showed increase of expression in the high glucose treatment
group whereas it significantly was attenuated in ASK1 inhibitor pre-treated
high glucose group. In ASK1 inhibition with Let7A overexpression group,
microglia was increased c-Myc mRNA level in high glucose condition than only
high glucose treatment group. GAPDH was used as a control. Each
experiment included the four repeats per condition. Data were expressed as
mean ± S.E.M, and were analyzed statistically using One-Way ANOVA,
followed by Bonferroni’s post hoc. *p < 0.05, **p < 0.001. RQ, relative
quantitative value of mRNA. ASK1 inhibitor, ASK1 inhibitor (600 nM)
pre-treatment and high glucose injury group/The inhibition of ASK1 activation
group; Let7A mimic. Let7A over expression group in high glucose condition.
regulating ASK1 activation under glucose-induced stress. IL-10
is an anti-inflammatory cytokine that inhibits the production
of pro-inflammatory cytokines including TNF-α, IL-1, and IL-
6 (Joyce et al., 1994; Joyce and Steer, 1996; Sawada et al.,
1999) in response to oxidative stress (Ledeboer et al., 2000;
Molina-Holgado et al., 2001; Szczepanik et al., 2001), and its
expression is also correlated with protection against neuronal
damage (de Waal Malefyt et al., 1991; Fiorentino et al., 1991;
Froen et al., 2002). Also, gene delivery of either IL-10 in the rat
hippocampus alleviates deficits in learning and memory function
(Lynch et al., 2004; Nolan et al., 2005). Based on our results,
the promotion of IL-10 by miR-Let7A transfection may suppress
the inflammatory response and protect neurons via ASK1
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activation in hyperglycemic conditions. The Myc protein, as an
unstable nuclear phosphorylated protein, is involved in many
cellular mechanisms (Hann and Eisenman, 1984; Ramsay et al.,
1986). c-Myc induces apoptosis signaling with mitogenic signals
(Prendergast, 1999). c-Myc protein is phosphorylated at both Ser-
62 and Ser-71 by JNK (Noguchi et al., 1999) and is linked to ASK1
signaling (Noguchi et al., 2001). c-Myc triggers the activation
of ASK1 and the mitochondrial apoptosis pathway (Evan and
Littlewood, 1998; Noguchi et al., 1999; Desbiens et al., 2003)
and induces cell proliferation (Sears et al., 1999). Furthermore,
c-Myc is a crucial factor in both ribosome biogenesis and
p53 stabilization (Menne et al., 2007; Dai and Lu, 2008; Kim
et al., 2011). A recent study demonstrates that the inhibition
of p38 and ASK1 reduces N-myc transcript levels (Guldal
et al., 2012). N-myc triggers the apoptosis of neuroblastoma
in hypoxia stress (Rossler et al., 2001). In hepatocytes, N-myc
also leads to apoptosis following serum deprivation (Ueda and
Ganem, 1996). N-myc was originally identified by oncogene
expression profiling of human neuroblastoma cells (Schwab
et al., 1983). The elevated expression of N-myc increases the
susceptibility of neuroblastoma cells to diverse types of cell
death signaling (Schweigerer et al., 1990; Malynn et al., 2000;
Rossler et al., 2001). In addition, N-myc plays a crucial role
in microglia function by regulating inflammatory mediators
(Jung et al., 2005). Several researchers have discovered that
the N-myc downstream-regulated gene 2 (Ndrg2) plays a key
role in reactive astrogliosis involving IL-6/STAT3 signaling
(Takarada-Iemata et al., 2014), and N-myc controls cytokine-
induced regulator IRE1 protein and c-Jun N-terminal kinase
in pancreatic beta cells (Brozzi et al., 2014). Considering our
results, we speculate that miR-Let7A regulates the expression
of c-Myc and N-myc by involving ASK1 activation in high-
glucose conditions and that miR-Let7A may also be associated
with the cytokine secretion pathway by regulating c-Myc and
N-Myc protein. In conclusion, we suggest that miR-Let7A may
affect microglia by involving ASK1 activation in hyperglycemia.
The results of the present study increase our understanding
of the relationship between miR-Let7A and ASK1 and the
function of microglia in hyperglycemia-induced oxidative
stress.
Author Contributions
JS performed the experiences and drafted the manuscript. JL
discussed the findings and helped draft the manuscript.
Acknowledgments
This research was supported by the Basic Science Research
Program through the National Research Foundation of Korea
(NRF) funded by the Ministry of Education, Science, and
Technology (NRF-2014R1A2A2A01006556).
References
Arango, D., Diosa-Toro, M., Rojas-Hernandez, L. S., Cooperstone, J. L., Schwartz,
S. J., Mo, X., et al. (2015). Dietary apigenin reduces LPS-induced expression of
miR-155 restoring immune balance during inflammation.Mol. Nutr. Food Res.
59, 763–772. doi: 10.1002/mnfr.201400705
Arnal, E., Miranda, M., Barcia, J., Bosch-Morell, F., and Romero, F. J. (2010).
Lutein and docosahexaenoic acid prevent cortex lipid peroxidation in
streptozotocin-induced diabetic rat cerebral cortex.Neuroscience 166, 271–278.
doi: 10.1016/j.neuroscience.2009.12.028
Baldeon, R. L., Weigelt, K., de Wit, H., Ozcan, B., van Oudenaren, A.,
Sempertegui, F., et al. (2014). Decreased serum level of miR-146a as sign of
chronic inflammation in type 2 diabetic patients. PLoS ONE 9:e115209. doi:
10.1371/journal.pone.0115209
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116, 281–297. doi: 10.1016/S0092-8674(04)00045-5
Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., et al. (2005).
Identification of hundreds of conserved and nonconserved humanmicroRNAs.
Nat. Genet. 37, 766–770. doi: 10.1038/ng1590
Brozzi, F., Gerlo, S., Grieco, F. A., Nardelli, T. R., Lievens, S., Gysemans, C.,
et al. (2014). A combined “omics” approach identifies N-Myc interactor as
a novel cytokine-induced regulator of IRE1 protein and c-Jun N-terminal
kinase in pancreatic beta cells. J. Biol. Chem. 289, 20677–20693. doi:
10.1074/jbc.M114.568808
Cai, B., Pan, Z., and Lu, Y. (2010). The roles of microRNAs in heart
diseases: a novel important regulator. Curr. Med. Chem. 17, 407–411. doi:
10.2174/092986710790226129
Catanzaro, O., Capponi, J. A., Michieli, J., Labal, E., Di Martino, I., and Sirois,
P. (2013). Bradykinin B(1) antagonism inhibits oxidative stress and restores
Na+K+ ATPase activity in diabetic rat peripheral nervous system. Peptides 44,
100–104. doi: 10.1016/j.peptides.2013.01.019
Cheng, Y. Q., Ren, J. P., Zhao, J., Wang, J. M., Zhou, Y., Li, G. Y., et al. (2015).
miR-155 regulates IFN-gamma production in NK cells via Tim-3 signaling in
chronic HCV infection. Immunology. doi: 10.1111/imm.12463. [Epub ahead of
print].
Cherry, J. D., Olschowka, J. A., and O’Banion, M. K. (2014). Neuroinflammation
and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation
11:98. doi: 10.1186/1742-2094-11-98
Colton, C., and Wilcock, D. M. (2010). Assessing activation states
in microglia. CNS Neurol. Disord. Drug Targets 9, 174–191. doi:
10.2174/187152710791012053
Colton, C. A. (2009). Heterogeneity of microglial activation in the innate
immune response in the brain. J. Neuroimmune Pharmacol. 4, 399–418. doi:
10.1007/s11481-009-9164-4
Dai, M. S., and Lu, H. (2008). Crosstalk between c-Myc and ribosome in ribosomal
biogenesis and cancer. J. Cell. Biochem. 105, 670–677. doi: 10.1002/jcb.
21895
Desbiens, K. M., Deschesnes, R. G., Labrie, M. M., Desfosses, Y., Lambert, H.,
Landry, J., et al. (2003). c-Myc potentiates the mitochondrial pathway of
apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1)
in the p38 signalling cascade. Biochem. J. 372, 631–641. doi: 10.1042/BJ200
21565
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., and de Vries, J. E.
(1991). Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes:
an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174,
1209–1220. doi: 10.1084/jem.174.5.1209
Dey, N., Bera, A., Das, F., Ghosh-Choudhury, N., Kasinath, B. S., and
Choudhury, G. G. (2015). High glucose enhances microRNA-26a to
activate mTORC1 for mesangial cell hypertrophy and matrix protein
expression. Cell. Signal. 27, 1276–1285. doi: 10.1016/j.cellsig.2015.
03.007
Dringen, R. (2005). Oxidative and antioxidative potential of brain microglial
cells. Antioxid. Redox Signal. 7, 1223–1233. doi: 10.1089/ars.2005.
7.1223
Du, T., and Zamore, P. D. (2005). microPrimer: the biogenesis and function of
microRNA. Development 132, 4645–4652. doi: 10.1242/dev.02070
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 May 2015 | Volume 9 | Article 198
Song and Lee miR-Let7A and ASK1 in microglia
Duarte, A. I., Santos, P., Oliveira, C. R., Santos, M. S., and Rego, A.
C. (2008). Insulin neuroprotection against oxidative stress is mediated
by Akt and GSK-3beta signaling pathways and changes in protein
expression. Biochim. Biophys. Acta 1783, 994–1002. doi: 10.1016/j.bbamcr.2008.
02.016
Echavarria, R., Mayaki, D., Neel, J. C., Harel, S., Sanchez, V., and Hussain, S.
N. (2015). Angiopoietin-1 inhibits Toll-like receptor 4 signaling in cultured
endothelial cells: role of miR-146b-5p. Cardiovasc. Res. doi: 10.1093/cvr/
cvv120. [Epub ahead of print].
Evan, G., and Littlewood, T. (1998). A matter of life and cell death. Science 281,
1317–1322. doi: 10.1126/science.281.5381.1317
Feng, B., Chen, S., George, B., Feng, Q., and Chakrabarti, S. (2010). miR133a
regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab. Res. Rev. 26,
40–49. doi: 10.1002/dmrr.1054
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., and O’Garra,
A. (1991). IL-10 inhibits cytokine production by activated macrophages.
J. Immunol. 147, 3815–3822.
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., and Tansey, M. G. (2009).
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol.
Neurodegener. 4:47. doi: 10.1186/1750-1326-4-47
Froen, J. F., Munkeby, B. H., Stray-Pedersen, B., and Saugstad, O. D.
(2002). Interleukin-10 reverses acute detrimental effects of endotoxin-induced
inflammation on perinatal cerebral hypoxia-ischemia. Brain Res. 942, 87–94.
doi: 10.1016/S0006-8993(02)02700-2
Guldal, C. G., Ahmad, A., Korshunov, A., Squatrito, M., Awan, A., Mainwaring, L.
A., et al. (2012). An essential role for p38 MAPK in cerebellar granule neuron
precursor proliferation. Acta Neuropathol. doi: 10.1007/s00401-012-0946-z.
[Epub ahead of print].
Hanisch, U. K. (2002). Microglia as a source and target of cytokines. Glia 40,
140–155. doi: 10.1002/glia.10161
Hann, S. R., and Eisenman, R. N. (1984). Proteins encoded by the human c-
myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol. 4,
2486–2497.
Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., et al.
(1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that
activates SAPK/JNK and p38 signaling pathways. Science 275, 90–94. doi:
10.1126/science.275.5296.90
Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2009). An epigenetic switch involving
NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell
transformation. Cell 139, 693–706. doi: 10.1016/j.cell.2009.10.014
Jiang, Q., Yuan, Y., Zhou, J., Wu, Y., Zhou, Q., Gui, S., et al. (2015). Apoptotic
events induced by high glucose in human hepatoma HepG2 cells involve
endoplasmic reticulum stress and MAPK’s activation. Mol. Cell. Biochem. 399,
113–122. doi: 10.1007/s11010-014-2238-5
Joyce, D. A., Gibbons, D. P., Green, P., Steer, J. H., Feldmann, M., and Brennan, F.
M. (1994). Two inhibitors of pro-inflammatory cytokine release, interleukin-
10 and interleukin-4, have contrasting effects on release of soluble p75
tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 24,
2699–2705. doi: 10.1002/eji.1830241119
Joyce, D. A., and Steer, J. H. (1996). IL-4, IL-10 and IFN-gamma have distinct,
but interacting, effects on differentiation-induced changes in TNF-alpha and
TNF receptor release by cultured human monocytes. Cytokine 8, 49–57. doi:
10.1006/cyto.1996.0007
Jung, D. Y., Lee, H., and Suk, K. (2005). Pro-apoptotic activity of N-myc in
activation-induced cell death of microglia. J. Neurochem. 94, 249–256. doi:
10.1111/j.1471-4159.2005.03186.x
Kim, H. D., Kim, T. S., and Kim, J. (2011). Aberrant ribosome biogenesis activates
c-Myc and ASK1 pathways resulting in p53-dependent G1 arrest. Oncogene 30,
3317–3327. doi: 10.1038/onc.2011.47
Klein, J. P., Hains, B. C., Craner, M. J., Black, J. A., and Waxman, S. G. (2004).
Apoptosis of vasopressinergic hypothalamic neurons in chronic diabetes
mellitus. Neurobiol. Dis. 15, 221–228. doi: 10.1016/j.nbd.2003.10.009
Knudsen, G. M., Jakobsen, J., Barry, D. I., Compton, A. M., and Tomlinson,
D. R. (1989). Myo-inositol normalizes decreased sodium permeability of the
blood-brain barrier in streptozotocin diabetes. Neuroscience 29, 773–777. doi:
10.1016/0306-4522(89)90148-6
Kodl, C. T., Franc, D. T., Rao, J. P., Anderson, F. S., Thomas, W., Mueller, B.
A., et al. (2008). Diffusion tensor imaging identifies deficits in white matter
microstructure in subjects with type 1 diabetes that correlate with reduced
neurocognitive function. Diabetes 57, 3083–3089. doi: 10.2337/db08-0724
Krady, J. K., Basu, A., Allen, C. M., Xu, Y., LaNoue, K. F., Gardner, T. W., et al.
(2005). Minocycline reduces proinflammatory cytokine expression, microglial
activation, and caspase-3 activation in a rodent model of diabetic retinopathy.
Diabetes 54, 1559–1565. doi: 10.2337/diabetes.54.5.1559
Kreutzberg, G. W. (1996). Microglia: a sensor for pathological events in the CNS.
Trends Neurosci. 19, 312–318. doi: 10.1016/0166-2236(96)10049-7
Ledeboer, A., Breve, J. J., Poole, S., Tilders, F. J., and Van Dam,
A. M. (2000). Interleukin-10, interleukin-4, and transforming
growth factor-beta differentially regulate lipopolysaccharide-induced
production of pro-inflammatory cytokines and nitric oxide in co-
cultures of rat astroglial and microglial cells. Glia 30, 134–142. doi:
10.1002/(SICI)1098-1136(200004)30:2<134::AID-GLIA3>3.0.CO;2-3
Lemstra, A. W., Groen in’t Woud, J. C., Hoozemans, J. J., van Haastert, E. S.,
Rozemuller, A. J., Eikelenboom, P., et al. (2007). Microglia activation in sepsis:
a case-control study. J. Neuroinflammation 4:4. doi: 10.1186/1742-2094-4-4
Li, Z. G., and Sima, A. A. (2004). C-peptide and central nervous
system complications in diabetes. Exp. Diabesity Res. 5, 79–90. doi:
10.1080/15438600490424550
Li, Z. G., Zhang, W., Grunberger, G., and Sima, A. A. (2002). Hippocampal
neuronal apoptosis in type 1 diabetes. Brain Res. 946, 221–231. doi:
10.1016/S0006-8993(02)02887-1
Li, Z. G., Zhang, W., and Sima, A. A. (2003). C-peptide enhances insulin-mediated
cell growth and protection against high glucose-induced apoptosis in SH-SY5Y
cells. Diabetes Metab. Res. Rev. 19, 375–385. doi: 10.1002/dmrr.389
Lin, X., You, Y., Wang, J., Qin, Y., Huang, P., and Yang, F. (2014). MicroRNA-
155 deficiency promotes nephrin acetylation and attenuates renal damage
in hyperglycemia-induced nephropathy. Inflammation 38, 546–554. doi:
10.1007/s10753-014-9961-7
Liu, H., Xu, R., Feng, L., Guo, W., Cao, N., Qian, C., et al. (2012). A novel
chromone derivative with anti-inflammatory property via inhibition of ROS-
dependent activation of TRAF6-ASK1-p38 pathway. PLoS ONE 7:e37168. doi:
10.1371/journal.pone.0037168
Lu, H., Buchan, R. J., and Cook, S. A. (2010). MicroRNA-223 regulates Glut4
expression and cardiomyocyte glucose metabolism. Cardiovasc. Res. 86,
410–420. doi: 10.1093/cvr/cvq010
Lynch, A. M., Walsh, C., Delaney, A., Nolan, Y., Campbell, V. A., and Lynch, M.
A. (2004). Lipopolysaccharide-induced increase in signalling in hippocampus
is abrogated by IL-10–a role for IL-1 beta? J. Neurochem. 88, 635–646. doi:
10.1046/j.1471-4159.2003.02157.x
Malynn, B. A., de Alboran, I. M., O’Hagan, R. C., Bronson, R., Davidson, L.,
DePinho, R. A., et al. (2000). N-myc can functionally replace c-myc in murine
development, cellular growth, and differentiation. Genes Dev. 14, 1390–1399.
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., and Locati, M.
(2004). The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol. 25, 677–686. doi: 10.1016/j.it.2004.09.015
Marin, T., Gongol, B., Chen, Z., Woo, B., Subramaniam, S., Chien, S.,
et al. (2013). Mechanosensitive microRNAs-role in endothelial responses
to shear stress and redox state. Free Radic. Biol. Med. 64, 61–68. doi:
10.1016/j.freeradbiomed.2013.05.034
Martinez, F. O., Sica, A., Mantovani, A., and Locati, M. (2008). Macrophage
activation and polarization. Front. Biosci. 13, 453–461. doi: 10.2741/2692
Martinez, J., and Tuschl, T. (2004). RISC is a 5′ phosphomonoester-producing
RNA endonuclease. Genes Dev. 18, 975–980. doi: 10.1101/gad.1187904
Matsuzawa, A., Saegusa, K., Noguchi, T., Sadamitsu, C., Nishitoh, H., Nagai, S.,
et al. (2005). ROS-dependent activation of the TRAF6-ASK1-p38 pathway is
selectively required for TLR4-mediated innate immunity. Nat. Immunol. 6,
587–592. doi: 10.1038/ni1200
McCrimmon, R. J., Ryan, C. M., and Frier, B. M. (2012). Diabetes and cognitive
dysfunction. Lancet 379, 2291–2299. doi: 10.1016/S0140-6736(12)60360-2
Menne, T. F., Goyenechea, B., Sanchez-Puig, N., Wong, C. C., Tonkin, L. M.,
Ancliff, P. J., et al. (2007). The Shwachman-Bodian-Diamond syndrome protein
mediates translational activation of ribosomes in yeast.Nat. Genet. 39, 486–495.
doi: 10.1038/ng1994
Min, K. J., Jou, I., and Joe, E. (2003). Plasminogen-induced IL-1beta and TNF-
alpha production in microglia is regulated by reactive oxygen species. Biochem.
Biophys. Res. Commun. 312, 969–974. doi: 10.1016/j.bbrc.2003.11.010
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 May 2015 | Volume 9 | Article 198
Song and Lee miR-Let7A and ASK1 in microglia
Molina-Holgado, F., Grencis, R., and Rothwell, N. J. (2001). Actions of exogenous
and endogenous IL-10 on glial responses to bacterial LPS/cytokines. Glia
33, 97–106. doi: 10.1002/1098-1136(200102)33:2<97::AID-GLIA1009>3.0.
CO;2-N
Mulder, R., Banete, A., and Basta, S. (2014). Spleen-derived macrophages are
readily polarized into classically activated (M1) or alternatively activated (M2)
states. Immunobiology 219, 737–745. doi: 10.1016/j.imbio.2014.05.005
Musen, G., Lyoo, I. K., Sparks, C. R., Weinger, K., Hwang, J., Ryan, C.
M., et al. (2006). Effects of type 1 diabetes on gray matter density
as measured by voxel-based morphometry. Diabetes 55, 326–333. doi:
10.2337/diabetes.55.02.06.db05-0520
Noguchi, K., Kitanaka, C., Yamana, H., Kokubu, A., Mochizuki, T., and Kuchino,
Y. (1999). Regulation of c-Myc through phosphorylation at Ser-62 and
Ser-71 by c-Jun N-terminal kinase. J. Biol. Chem. 274, 32580–32587. doi:
10.1074/jbc.274.46.32580
Noguchi, K., Kokubu, A., Kitanaka, C., Ichijo, H., and Kuchino, Y. (2001). ASK1-
signaling promotes c-Myc protein stability during apoptosis. Biochem. Biophys.
Res. Commun. 281, 1313–1320. doi: 10.1006/bbrc.2001.4498
Nolan, Y., Maher, F. O., Martin, D. S., Clarke, R. M., Brady, M. T., Bolton,
A. E., et al. (2005). Role of interleukin-4 in regulation of age-related
inflammatory changes in the hippocampus. J. Biol. Chem. 280, 9354–9362. doi:
10.1074/jbc.M412170200
Osaka, N., Takahashi, T., Murakami, S., Matsuzawa, A., Noguchi, T., Fujiwara,
T., et al. (2007). ASK1-dependent recruitment and activation of macrophages
induce hair growth in skin wounds. J. Cell Biol. 176, 903–909. doi:
10.1083/jcb.200611015
Osipova, J., Fischer, D. C., Dangwal, S., Volkmann, I., Widera, C., Schwarz, K.,
et al. (2014). Diabetes-associated microRNAs in pediatric patients with type 1
diabetes mellitus: a cross-sectional cohort study. J. Clin. Endocrinol. Metab. 99,
E1661–E1665. doi: 10.1210/jc.2013-3868
Perez, L. M., Bernal, A., San Martin, N., Lorenzo, M., Fernandez-Veledo, S., and
Galvez, B. G. (2013). Metabolic rescue of obese adipose-derived stem cells by
Lin28/Let7 pathway. Diabetes 62, 2368–2379. doi: 10.2337/db12-1220
Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S.,
et al. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis
associated with chronic colitis. J. Clin. Invest. 118, 560–570.
Prendergast, G. C. (1999). Mechanisms of apoptosis by c-Myc. Oncogene 18,
2967–2987. doi: 10.1038/sj.onc.1202727
Quan, Y., Du, J., and Wang, X. (2007). High glucose stimulates GRO secretion
from rat microglia via ROS, PKC, and NF-kappaB pathways. J. Neurosci. Res.
85, 3150–3159. doi: 10.1002/jnr.21421
Quan, Y., Jiang, C. T., Xue, B., Zhu, S. G., and Wang, X. (2011). High glucose
stimulates TNFalpha and MCP-1 expression in rat microglia via ROS and NF-
kappaB pathways. Acta Pharmacol. Sin. 32, 188–193. doi: 10.1038/aps.2010.174
Quinn, S. R., and O’Neill, L. A. (2011). A trio of microRNAs that control Toll-like
receptor signalling. Int. Immunol. 23, 421–425. doi: 10.1093/intimm/dxr034
Ramsay, G., Stanton, L., Schwab, M., and Bishop, J. M. (1986). Human proto-
oncogene N-myc encodes nuclear proteins that bind DNA. Mol. Cell. Biol. 6,
4450–4457.
Rossler, J., Schwab, M., Havers, W., and Schweigerer, L. (2001). Hypoxia promotes
apoptosis of human neuroblastoma cell lines with enhanced N-myc expression.
Biochem. Biophys. Res. Commun. 281, 272–276. doi: 10.1006/bbrc.2001.4342
Sawada, M., Suzumura, A., Hosoya, H., Marunouchi, T., and Nagatsu, T. (1999).
Interleukin-10 inhibits both production of cytokines and expression of cytokine
receptors in microglia. J. Neurochem. 72, 1466–1471. doi: 10.1046/j.1471-
4159.1999.721466.x
Schamberger, A., Sarkadi, B., and Orban, T. I. (2012). Human mirtrons can
express functional microRNAs simultaneously from both arms in a flanking
exon-independent manner. RNA Biol. 9, 1177–1185. doi: 10.4161/rna.21359
Schulte, L. N., Westermann, A. J., and Vogel, J. (2013). Differential activation and
functional specialization of miR-146 and miR-155 in innate immune sensing.
Nucleic Acids Res. 41, 542–553. doi: 10.1093/nar/gks1030
Schwab,M., Alitalo, K., Klempnauer, K. H., Varmus, H. E., Bishop, J. M., Gilbert, F.,
et al. (1983). AmplifiedDNAwith limited homology tomyc cellular oncogene is
shared by human neuroblastoma cell lines and a neuroblastoma tumour.Nature
305, 245–248. doi: 10.1038/305245a0
Schweigerer, L., Scheurich, P., and Fotsis, T. (1990). Enhanced MYCN oncogene
expression in human neuroblastoma cells results in increased susceptibility
to growth inhibition by TNF alpha. Biochem. Biophys. Res. Commun. 170,
1301–1307. doi: 10.1016/0006-291X(90)90535-U
Sears, R., Leone, G., DeGregori, J., and Nevins, J. R. (1999). Ras enhances Myc
protein stability.Mol. Cell 3, 169–179. doi: 10.1016/S1097-2765(00)80308-1
Shan, Z. X., Lin, Q. X., Deng, C. Y., Zhu, J. N., Mai, L. P., Liu, J. L., et al.
(2010). miR-1/miR-206 regulate Hsp60 expression contributing to glucose-
mediated apoptosis in cardiomyocytes. FEBS Lett. 584, 3592–3600. doi:
10.1016/j.febslet.2010.07.027
Sima, A. A., Kamiya, H., and Li, Z. G. (2004). Insulin, C-peptide, hyperglycemia,
and central nervous system complications in diabetes. Eur. J. Pharmacol. 490,
187–197. doi: 10.1016/j.ejphar.2004.02.056
Song, J., Cheon, S. Y., Jung, W., Lee, W. T., and Lee, J. E. (2014). Resveratrol
induces the expression of interleukin-10 and brain-derived neurotrophic factor
in BV2 microglia under hypoxia. Int. J. Mol. Sci. 15, 15512–15529. doi:
10.3390/ijms150915512
Sredy, J., Sawicki, D. R., and Notvest, R. R. (1991). Polyol pathway activity in
nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose
withdrawal or tolrestat intervention therapy. J. Diabet. Complications 5, 42–47.
doi: 10.1016/0891-6632(91)90010-M
Stein, M., Keshav, S., Harris, N., and Gordon, S. (1992). Interleukin 4 potently
enhances murine macrophage mannose receptor activity: a marker of
alternative immunologic macrophage activation. J. Exp. Med. 176, 287–292.
doi: 10.1084/jem.176.1.287
Szczepanik, A.M., Funes, S., Petko,W., and Ringheim, G. E. (2001). IL-4, IL-10 and
IL-13 modulate A beta(1–42)-induced cytokine and chemokine production in
primary murine microglia and a human monocyte cell line. J. Neuroimmunol.
113, 49–62. doi: 10.1016/S0165-5728(00)00404-5
Takarada-Iemata, M., Kezuka, D., Takeichi, T., Ikawa, M., Hattori, T.,
Kitao, Y., et al. (2014). Deletion of N-myc downstream-regulated gene
2 attenuates reactive astrogliosis and inflammatory response in a mouse
model of cortical stab injury. J. Neurochem. 130, 374–387. doi: 10.1111/jnc.
12729
Tan, Y., Yang, J., Xiang, K., Tan, Q., and Guo, Q. (2015). Suppression ofMicroRNA-
155 Attenuates neuropathic pain by regulating SOCS1 signalling pathway.
Neurochem. Res. 40, 550–560. doi: 10.1007/s11064-014-1500-2
Tobiume, K., Matsuzawa, A., Takahashi, T., Nishitoh, H., Morita, K., Takeda,
K., et al. (2001). ASK1 is required for sustained activations of JNK/p38
MAP kinases and apoptosis. EMBO Rep. 2, 222–228. doi: 10.1093/embo-
reports/kve046
Tsuda, M., Ueno, H., Kataoka, A., Tozaki-Saitoh, H., and Inoue, K. (2008).
Activation of dorsal horn microglia contributes to diabetes-induced tactile
allodynia via extracellular signal-regulated protein kinase signaling. Glia 56,
378–386. doi: 10.1002/glia.20623
Ueda, K., and Ganem, D. (1996). Apoptosis is induced by N-myc expression in
hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by
insulin-like growth factor II. J. Virol. 70, 1375–1383.
Urbich, C., Kuehbacher, A., and Dimmeler, S. (2008). Role of microRNAs
in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res. 79,
581–588. doi: 10.1093/cvr/cvn156
van Elderen, S. G., de Roos, A., de Craen, A. J., Westendorp, R. G., Blauw, G.
J., Jukema, J. W., et al. (2010). Progression of brain atrophy and cognitive
decline in diabetes mellitus: a 3-year follow-up. Neurology 75, 997–1002. doi:
10.1212/WNL.0b013e3181f25f06
Varin, A., and Gordon, S. (2009). Alternative activation of macrophages:
immune function and cellular biology. Immunobiology 214, 630–641. doi:
10.1016/j.imbio.2008.11.009
Varnum, M. M., and Ikezu, T. (2012). The classification of microglial activation
phenotypes on neurodegeneration and regeneration in Alzheimer’s disease
brain. Arch. Immunol. Ther. Exp. (Warsz). 60, 251–266. doi: 10.1007/s00005-
012-0181-2
Wang, F., Wu, Y., Gu, H., Reece, E. A., Fang, S., Gabbay-Benziv, R., et al. (2015).
Ask1 gene deletion blocks maternal diabetes-induced endoplasmic reticulum
stress in the developing embryo by disrupting the unfolded protein response
signalosome. Diabetes 64, 973–988. doi: 10.2337/db14-0409
Wang, H. J., Huang, Y. L., Shih, Y. Y., Wu, H. Y., Peng, C. T., and Lo, W. Y.
(2014). MicroRNA-146a decreases high glucose/thrombin-induced endothelial
inflammation by inhibiting NAPDH oxidase 4 expression.Mediators Inflamm.
2014:379537. doi: 10.1155/2014/379537
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 May 2015 | Volume 9 | Article 198
Song and Lee miR-Let7A and ASK1 in microglia
Wang, J. Y., Yang, J. M., Wang, J. Y., Tao, P. L., and Yang, S. N. (2001).
Synergistic apoptosis induced by bacterial endotoxin lipopolysaccharide and
high glucose in rat microglia. Neurosci. Lett. 304, 177–180. doi: 10.1016/S0304-
3940(01)01780-3
Wodarski, R., Clark, A. K., Grist, J., Marchand, F., and Malcangio, M. (2009).
Gabapentin reverses microglial activation in the spinal cord of streptozotocin-
induced diabetic rats. Eur. J. Pain 13, 807–811. doi: 10.1016/j.ejpain.2008.
09.010
Wojtera, M., Sobow, T., Kloszewska, I., Liberski, P. P., Brown, D. R., and
Sikorska, B. (2012). Expression of immunohistochemical markers on microglia
in Creutzfeldt-Jakob disease and Alzheimer’s disease: morphometric study and
review of the literature. Folia Neuropathol. 50, 74–84.
Xiao, J., Luo, X., Lin, H., Zhang, Y., Lu, Y., Wang, N., et al. (2007). MicroRNAmiR-
133 represses HERGK+ channel expression contributing to QT prolongation in
diabetic hearts. J. Biol. Chem. 282, 12363–12367. doi: 10.1074/jbc.C700015200
Xu, H., Chen,M., and Forrester, J. V. (2009). Para-inflammation in the aging retina.
Prog. Retin. Eye Res. 28, 348–368. doi: 10.1016/j.preteyeres.2009.06.001
Yang, J., Jiang, Z., Fitzgerald, D. C., Ma, C., Yu, S., Li, H., et al. (2009). Adult
neural stem cells expressing IL-10 confer potent immunomodulation and
remyelination in experimental autoimmune encephalitis. J. Clin. Invest. 119,
3678–3691. doi: 10.1172/JCI37914
Yokoi, T., Fukuo, K., Yasuda, O., Hotta,M.,Miyazaki, J., Takemura, Y., et al. (2006).
Apoptosis signal-regulating kinase 1 mediates cellular senescence induced by
high glucose in endothelial cells. Diabetes 55, 1660–1665. doi: 10.2337/db05-
1607
Yuk, J. M., Shin, D. M., Yang, C. S., Kim, K. H., An, S. J., Rho, J., et al. (2009).
Role of apoptosis-regulating signal kinase 1 in innate immune responsesby
Mycobacterium bovis bacillus Calmette-Guerin. Immunol. Cell Biol. 87,
100–107. doi: 10.1038/icb.2008.74
Zhang, X., Dong, H., Zhang, S., Lu, S., Sun, J., and Qian, Y. (2015). Enhancement
of LPS-induced microglial inflammation response via TLR4 under high glucose
conditions. Cel. Physiol. Biochem. 35, 1571–1581. doi: 10.1159/000373972
Zhang, Y. P., Eber, A., Yuan, Y., Yang, Z., Rodriguez, Y., Levitt, R. C., et al.
(2013). Prophylactic and antinociceptive effects of coenzyme Q10 on diabetic
neuropathic pain in a mouse model of type 1 diabetes. Anesthesiology 118,
945–954. doi: 10.1097/ALN.0b013e3182829b7b
Zhang, Z., Huang, L., Yu, Z., Chen, X., Yang, D., Zhan, P., et al. (2014). Let-
7a functions as a tumor suppressor in Ewing’s sarcoma cell lines partly
by targeting cyclin-dependent kinase 6. DNA Cell Biol. 33, 136–147. doi:
10.1089/dna.2013.2179
Zhu, H., Shyh-Chang, N., Segre, A. V., Shinoda, G., Shah, S. P., Einhorn,W. S., et al.
(2011). The Lin28/let-7 axis regulates glucose metabolism. Cell 147, 81–94. doi:
10.1016/j.cell.2011.08.033
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Song and Lee. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 May 2015 | Volume 9 | Article 198
